Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 960.89K | 681.35K | 253.57K | 223.21K | 1.16M | 2.55M |
Gross Profit | 277.54K | 222.81K | -220.98K | -209.16K | 309.60K | 1.48M |
EBITDA | -7.64M | -7.88M | -1.43M | -2.11M | -1.01M | -341.17K |
Net Income | -7.80M | -7.95M | -3.77M | -6.18M | -4.25M | -3.03M |
Balance Sheet | ||||||
Total Assets | 4.18M | 5.76M | 7.78M | 1.30M | 1.39M | 2.61M |
Cash, Cash Equivalents and Short-Term Investments | 1.97M | 3.39M | 2.14M | 264.87K | 115.40K | 191.70K |
Total Debt | 154.25K | 155.89K | 172.67K | 22.42M | 18.80M | 19.14M |
Total Liabilities | 1.84M | 1.80M | 2.99M | 25.45M | 19.55M | 20.68M |
Stockholders Equity | 2.43M | 4.04M | 4.87M | -23.58M | -17.58M | -17.50M |
Cash Flow | ||||||
Free Cash Flow | -3.36M | -5.83M | -4.66M | -1.07M | -684.50K | -238.28K |
Operating Cash Flow | -3.32M | -5.65M | -4.54M | -1.01M | -649.11K | -167.30K |
Investing Cash Flow | -97.91K | -1.89M | -115.89K | -60.13K | -35.39K | -70.98K |
Financing Cash Flow | 6.85M | 7.05M | 6.47M | 1.22M | 611.23K | 277.36K |
On September 9, 2025, 60 Degrees Pharmaceuticals, Inc. presented investor information highlighting the potential growth of ARAKODA, especially for chronic babesiosis, which could surpass its use for malaria prevention. The company faces challenges such as low brand recognition and competition from generic alternatives, but aims to address these through a commercial pilot program to increase awareness and differentiate ARAKODA in the market.
The most recent analyst rating on (SXTP) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. entered into an At-The-Market Sales Agreement with H.C. Wainwright & Co., LLC to offer and sell shares of its common stock, potentially raising up to $1,397,533. The agreement allows the company flexibility in selling shares while Wainwright acts as the sales agent, earning a 3% commission on sales. Additionally, on the same date, the company terminated a previous sales agreement with Wallachbeth Capital LLC, effective immediately, releasing both parties from any obligations.
The most recent analyst rating on (SXTP) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
On July 15, 2025, 60 Degrees Pharmaceuticals, Inc. announced a Securities Purchase Agreement with institutional investors for a follow-on offering, which included shares of common stock and various warrants. The offering, which closed on July 16, 2025, generated approximately $5 million in gross proceeds, intended for general corporate purposes and working capital. The offering was made under the company’s registration statement declared effective by the SEC. This move is expected to impact the company’s financial operations and market positioning by providing additional capital for its ongoing projects.
The most recent analyst rating on (SXTP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.